Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: Cymeed who wrote (662)	12/23/1997 6:38:00 PM
From: seminole	Respond to of 887

Cymeed <<<<And I doubt the viability of DepoFoam technology. There might be toxicity issues specificly related to DepoFoam which is unaware of by most shareholders.>>>> I am not aware of toxicity relating to Depofoam. Do you have information about this issue? I would suspect that the cancer drug provides the toxicity. So Who believes that 70% of the value of the company was the drug DepoCyt? If you do the current price is fair and you should sell. Who believes the value of the company lies with Depofoam and is independent of any one drug? If you do, I would not sell. Its my opinion that too much of the failed approval has been assumed to be depofoam related and to little of the failure linked to this cancer drug. richard